<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447031</url>
  </required_header>
  <id_info>
    <org_study_id>koh02</org_study_id>
    <nct_id>NCT00447031</nct_id>
  </id_info>
  <brief_title>Combination Therapy for Neovascular Age Related Macular Degeneration</brief_title>
  <official_title>Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone Acetonide Injection Versus Intravitreal Bevacizumab for Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exudative age related macular degeneration (ARMD) is most common cause of blindness in old
      population. It is clear that no single therapy addresses the multifactorial pathogenesis of
      the disease. Recently, studies of intravitreal anti-VEGF therapies such as pegaptanib and
      bevacizumab have shown the beneficial effect in visual acuity in the treatment of neovascular
      ARMD. However, the problem with these intravitreal injections is that therapy must be
      frequently administered for a prolonged but unknown period of time to maintain the benefit.
      Prolonged, frequent injections may be associated with additional safety risk,lack of
      convenience and high treatment cost.

      Intravitreal steroid injection with anti-inflammatory properties limits any further VEGF
      upregulation initiated by the inflammation which has been known as one of the pathogenesis
      and causes of recurrence after the treatment of the neovascular ARMD.

      The researchers hypothesize that the combined treatment of intravitreal bevacizumab and
      triamcinolone acetonide may decrease the recurrence rate after the treatment and obviate the
      frequent intravitreal injections in the treatment of neovascular ARMD.

      In this study, the researchers will compare the recurrence rate of combined treatment of
      intravitreal bevacizumab and triamcinolone acetonide versus intravitreal bevacizumab alone in
      the treatment of neovascular ARMD.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient patients who met inclusion criteria
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">November 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>best corrected visual acuity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>complication rate</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal bevacizumab and triamcinolone acetonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neovascular ARMD confirmed with 90+ noncontact lens biomicroscopy, fluorescein
             angiography, ocular coherence tomography

        Exclusion Criteria:

          -  Intractable systemic hypertension

          -  Recent myocardial infarct within 6 months at enrollment

          -  Recent cerebrovascular attack within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jun Koh</last_name>
    <role>Principal Investigator</role>
    <affiliation>YUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1273-80. Epub 2007 Feb 28.</citation>
    <PMID>17333238</PMID>
  </reference>
  <reference>
    <citation>Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007 Feb;27(2):133-40.</citation>
    <PMID>17290193</PMID>
  </reference>
  <reference>
    <citation>Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006 Nov-Dec;26(9):988-93.</citation>
    <PMID>17151484</PMID>
  </reference>
  <reference>
    <citation>Aisenbrey S, Ziemssen F, VÃ¶lker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8. Epub 2006 Dec 21.</citation>
    <PMID>17186262</PMID>
  </reference>
  <reference>
    <citation>Gomi F, Nishida K, Oshima Y, Sakaguchi H, Sawa M, Tsujikawa M, Tano Y. Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol. 2007 Mar;143(3):507-10. Epub 2006 Dec 8.</citation>
    <PMID>17317397</PMID>
  </reference>
  <reference>
    <citation>Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Sauder G, Spandau UH. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand. 2007 Aug;85(5):563-5. Epub 2007 Feb 27.</citation>
    <PMID>17324219</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <last_update_submitted>February 5, 2010</last_update_submitted>
  <last_update_submitted_qc>February 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2010</last_update_posted>
  <keyword>age related macular degeneration</keyword>
  <keyword>intravitreal bevacizumab</keyword>
  <keyword>intravitreal triamcinolone acetonide</keyword>
  <keyword>neovascular age related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

